Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Pharmacotherapy for obesity 1 - the need for pharmacotherapy in weight management
Published on December 31, 2018 14 min
A selection of talks on Metabolism & Nutrition
An introduction to exercise metabolism 1
- Prof. Emeritus Michael Gleeson
- Loughborough University, UK
Relapse in obesity management: does increased appetite and reduced energy expenditure play a role?
- Prof. Cátia Martins
- Norwegian University of Science and Technology, Norway
This lecture is about pharmacotherapy for obesity. I'm Jeo Prieto. I am Professor Emeritus at the University of Melbourne and the head of the Byte Control Clinic at Austin Health in Melbourne. I'm also chair of the Clinical Care Committee of World Obesity.
Before I start, I need to declare that I am currently chair of the Medical Advisory Board for Liraglutide in Australia for Novo Nordisk. I've also given lectures on Weight Management for iNova who market phentermine in Australia.
Some years ago, in fact in 2003 the National Health and Medical Research Council in Australia developed evidence-based guidelines for the management of obesity. As part of that, they've reviewed literature on various strategies for weight loss including: diets, exercise and psychological treatments and investigated the acute weight losses and then the two year outcomes of those weight loss strategies. In this slide, you see the effects of diet therapies on the left-hand column. You can see the types of diets that were found in the literature including; low fat, low energy, very low energy, meal replacements and there are different degrees of a fat losses from 3.9 which had low-fat diets to 11.8 with very low energy diets. But the weight-loss at two years was less as most patients regained the weight.